CN Patent

CN116981669B — 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途

Assigned to Shanghai Qilu Pharmaceutical Research and Development Centre Ltd · Expires 2024-08-30 · 2y expired

What this patent protects

公开了一种新型嘧啶/吡啶并杂环类腺苷受体抑制剂及其制备方法和用途，其为如式II所示的化合物、其药学上可接受的盐、其溶剂合物、或其药学上可接受的盐的溶剂合物。药物活性数据表明，该类化合物对A2a或/和A2b具有较好的抑制作用，且部分化合物表现出较好的选择性，可以用于治疗与A2a或/和A2b受体相关疾病。

USPTO Abstract

公开了一种新型嘧啶/吡啶并杂环类腺苷受体抑制剂及其制备方法和用途，其为如式II所示的化合物、其药学上可接受的盐、其溶剂合物、或其药学上可接受的盐的溶剂合物。药物活性数据表明，该类化合物对A2a或/和A2b具有较好的抑制作用，且部分化合物表现出较好的选择性，可以用于治疗与A2a或/和A2b受体相关疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN116981669B
Jurisdiction
CN
Classification
—
Expires
2024-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.